AstraZeneca: CHMP Recommends Approval Of Tezspire In The EU

AstraZeneca and Amgen's Tezspire (tezepelumab) has received a positive recommendation from the European Medicines Agency's CHMP for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adults, based on the WAYPOINT Phase III trial. This recommendation, coupled with ongoing regulatory reviews for CRSwNP in major markets like the US, China, and Japan, signals a significant market expansion opportunity for the drug beyond its existing severe asthma approval, potentially enhancing future revenue streams for both pharmaceutical companies.

Analysis

AstraZeneca (AZN) and Amgen (AMGN) have achieved a significant regulatory milestone for their drug, Tezspire (tezepelumab), with a positive recommendation for approval from the European Medicines Agency's CHMP. The recommendation is for a new indication, the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adults, and is supported by data from the WAYPOINT Phase III trial. This development signals a crucial label expansion beyond Tezspire's existing approval for severe asthma, which is already established in over 60 countries including the US, EU, and Japan. The positive EU opinion not only paves the way for commercialization in a new therapeutic area within Europe but also serves as a strong positive signal for pending regulatory reviews for the same indication in other major markets, including the US, China, and Japan. This expansion of Tezspire's addressable market represents a tangible catalyst for future revenue growth for both pharmaceutical partners.

Key Decisions for Investors

• Investors in AstraZeneca and Amgen should view this positive CHMP opinion as a key de-risking event that enhances the long-term revenue potential of Tezspire by adding a second major indication.
• It is now critical to monitor the upcoming regulatory decisions for this new indication in the US, China, and Japan, as approvals in these large markets would materially increase the drug's peak sales forecasts.
• Consider adjusting valuation models for both AZN and AMGN to reflect the increased probability of success and the potential market size of Tezspire in the chronic rhinosinusitis with nasal polyps segment.